Speaker articles
Take a look at what some of our Hallmarks of Cancer speakers have published recently and chat with them about their work in San Diego, USA.
Keynote speakers
Carl June, University of Pennsylvania, Philadelphia, USA
The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function
Jennifer Wargo, The University of Texas MD Anderson Cancer Center, Houston, USA
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Speakers
Timothy Chan, Cleveland Clinic, Cleveland, USA
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
Lisa Coussens, Oregon Health & Science University, USA
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
Maximilian Diehn, Stanford University, Stanford, USA
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
Philip Greenberg, Fred Hutchinson Cancer Research Center, Seattle, USA
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
John Haanen, The Netherlands Cancer Institute, Amsterdam, Netherlands
Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
Han Liang, The University of Texas MD Anderson Cancer Center, Houston, USA
A functional genomic approach to actionable gene fusions for precision oncology
Howard Hang , Scripps Research, San Diego, USA
Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
Rob Knight, University of California at San Diego, San Diego, USA
Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection
Antoni Ribas, University of California at Los Angeles, Los Angeles, USA
Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma
Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
Andrea Schietinger, Memorial Sloan Kettering Caner Center, USA
TOX is a critical regulator of tumour-specific T cell differentiation
Ravid Straussman, Weizmann Institute of Science, Rehovot, Israel
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer
Charles Swanton, The Francis Crick Institute, London, UK
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Suzanne Topalian, Johns Hopkins Medicine, Baltimore, USA
The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas
David Tuveson, Cold Spring Harbor Laboratory, New York, USA
Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer
Karin de Visser, The Netherlands Cancer Institute, Amsterdam, Netherlands
Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche
Catherine Wu, Dana-Farber Cancer Institute, Boston, USA
Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer
Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
